Abstract
Recurrent HCV is universal after liver transplantation in patients viremic at the time of transplantation and leads to cirrhosis in up to 30% of patients by five years. Once cirrhosis develops, the risk of hepatic decompensation is 42% per year. This has led to recurrent HCV emerging as an important yet controversial indication for liver retransplantation and a renewed interest in the role of anti-viral therapies. Despite encouraging results with pegylated interferon and ribavirin in the non-transplant HCV population, these findings have not translated to transplant recipients where viral eradication is frequently unsuccessful for genotype 1 patients (
| Original language | English |
|---|---|
| Pages (from-to) | 34-40 |
| Number of pages | 7 |
| Journal | Anti-Infective Agents |
| Volume | 10 |
| Issue number | 1 |
| State | Published - 2012 |
| Externally published | Yes |
Fingerprint
All Science Journal Classification (ASJC) codes
- Infectious Diseases
- Pharmacology
Cite this
Recurrent hepatitis C after liver transplantation. / Mukherjee, Sandeep.
In: Anti-Infective Agents, Vol. 10, No. 1, 2012, p. 34-40.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Recurrent hepatitis C after liver transplantation
AU - Mukherjee, Sandeep
PY - 2012
Y1 - 2012
N2 - Recurrent HCV is universal after liver transplantation in patients viremic at the time of transplantation and leads to cirrhosis in up to 30% of patients by five years. Once cirrhosis develops, the risk of hepatic decompensation is 42% per year. This has led to recurrent HCV emerging as an important yet controversial indication for liver retransplantation and a renewed interest in the role of anti-viral therapies. Despite encouraging results with pegylated interferon and ribavirin in the non-transplant HCV population, these findings have not translated to transplant recipients where viral eradication is frequently unsuccessful for genotype 1 patients (
AB - Recurrent HCV is universal after liver transplantation in patients viremic at the time of transplantation and leads to cirrhosis in up to 30% of patients by five years. Once cirrhosis develops, the risk of hepatic decompensation is 42% per year. This has led to recurrent HCV emerging as an important yet controversial indication for liver retransplantation and a renewed interest in the role of anti-viral therapies. Despite encouraging results with pegylated interferon and ribavirin in the non-transplant HCV population, these findings have not translated to transplant recipients where viral eradication is frequently unsuccessful for genotype 1 patients (
UR - http://www.scopus.com/inward/record.url?scp=84867509853&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84867509853&partnerID=8YFLogxK
M3 - Article
VL - 10
SP - 34
EP - 40
JO - Anti-Infective Agents
JF - Anti-Infective Agents
SN - 2211-3525
IS - 1
ER -